Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study
European Journal of Neurology · 2025
DOI: 10.1111/ene.70429 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Yusuf A Rajabally und 3 weiteren Autor:innen. Beteiligte Einrichtung: Aston Medical School, Aston University, Birmingham, UK. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunologic Factors, Immunoglobulins, Intravenous, Immunoglobulins. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Immunoglobulin dosing is individualised in chronic inflammatory demyelinating polyneuropathy (CIDP).
Methods
We retrospectively compared differences in presentation/outcomes/side effects in subjects on very high dose immunoglobulin defined as ≥ 2 g/kg every 3 weeks (‘Group A’) and subjects on ≤ 1 g/kg every 3 weeks (‘Group B’), from 2 UK centres.
Results
One‐hundred and eight subjects with CIDP received immunoglobulins. Group A consisted of 12 subjects (11.1%). Mean dose was 2.63 g/kg every 3 weeks (SD: 0.71). Six subjects (50%) had typical CIDP, 3 (25%) had motor CIDP, and 3 (25%) had multifocal CIDP. Group B consisted of 40 subjects (37%) on a mean dose of 0.47 g/kg every 3 weeks (SD: 0.16). Compared to subjects from Group B, subjects from Group A had greater pre‐treatment disability ( p = 0.029), more common associated autoimmune disease ( p = 0.034), worse post‐treatment outcome ( p = 0.005) and a longer time to maximal improvement ( p = 0.041). No differences were found between the two groups for age/gender/weight/acuteness of presentation/side‐effects. Occurrence of any side‐effect ( p = 0.005), and of thromboembolic complication ( p = 0.022), were associated with presence of another autoimmune disease.
Conclusions
Very high dose immunoglobulin may be partially effective in a minority of subjects with CIDP. Subjects treated with very high dose immunoglobulin may have greater pre‐treatment disability, be more likely to have another autoimmune disease, have worse post‐treatment outcomes, and take longer to reach maximal improvement, than subjects on lower doses. Concurrent autoimmune disease may increase immunoglobulin‐induced thromboembolic risk. Earlier consideration of alternative therapies may be more appropriate than immunoglobulin dose escalation in subjects with suboptimal immunoglobulin response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aston Medical School, Aston University, Birmingham, UK.
- Inflammatory Neuropathy Service, Department of Neurology, University Hospitals Birmingham, Birmingham, UK.
- Wessex Neurological Centre, University Hospital Southampton, Southampton, UK.
- Department of Neurology, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Yusuf A Rajabally, Young Gi Min, Chinar Osman
Zitieren
APA
Rajabally, Y. A., Freiha, J., Min, Y. G., & Osman, C. (2025). Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study. European Journal of Neurology. https://doi.org/10.1111/ene.70429
Vancouver
Rajabally YA, Freiha J, Min YG, Osman C. Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study. European Journal of Neurology. 2025. doi:10.1111/ene.70429
BibTeX
@article{Rajabally2025,
author = {Rajabally, Yusuf A and Freiha, Joumana and Min, Young Gi and Osman, Chinar},
title = {Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70429}
}
EUVIMED